Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores
- PMID: 10465711
- DOI: 10.1016/s0304-3940(99)00311-0
Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores
Abstract
A growing body of evidence suggests that the non-Abeta component of Alzheimer's disease amyloid precursor protein (NACP) or alpha-synuclein contributes to the neurodegenerative processes in Alzheimer's disease (AD), Parkinson's disease (PD) and dementia with Lewy bodies (DLB). In the present study antisera to the N terminus and the NAC domain of the alpha-synuclein protein were employed to elucidate the expression pattern in brains of patients with AD, PD, DLB and control specimen. Alpha-synuclein exhibited an overall punctuate expression profile compatible with a synaptic function. Interestingly, while Lewy bodies were strongly immunoreactive, none of the alpha-synuclein antisera revealed staining in mature beta-amyloid plaques in AD. These observations suggest that alpha-synuclein does not contribute to late neurodegenerative processes in AD brains.
Similar articles
-
Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid.Am J Pathol. 1999 Oct;155(4):1173-81. doi: 10.1016/s0002-9440(10)65220-0. Am J Pathol. 1999. PMID: 10514400 Free PMC article.
-
Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases.Neurobiol Aging. 2005 Aug-Sep;26(8):1183-92. doi: 10.1016/j.neurobiolaging.2004.10.006. Epub 2004 Dec 28. Neurobiol Aging. 2005. PMID: 15917102
-
Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies.Brain Res. 1999 Oct 2;843(1-2):53-61. doi: 10.1016/s0006-8993(99)01848-x. Brain Res. 1999. PMID: 10528110
-
Properties of NACP/alpha-synuclein and its role in Alzheimer's disease.Biochim Biophys Acta. 2000 Jul 26;1502(1):95-109. doi: 10.1016/s0925-4439(00)00036-3. Biochim Biophys Acta. 2000. PMID: 10899435 Review.
-
Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.Neuromolecular Med. 2003;4(1-2):21-36. doi: 10.1385/NMM:4:1-2:21. Neuromolecular Med. 2003. PMID: 14528050 Review.
Cited by
-
Insoluble alpha-synuclein in Alzheimer's disease without Lewy body formation.Neurotox Res. 2005;7(1-2):69-76. doi: 10.1007/BF03033777. Neurotox Res. 2005. PMID: 15639799
-
Specific antibodies to soluble alpha-synuclein conformations in intravenous immunoglobulin preparations.Clin Exp Immunol. 2010 Sep;161(3):527-35. doi: 10.1111/j.1365-2249.2010.04214.x. Clin Exp Immunol. 2010. PMID: 20646004 Free PMC article.
-
Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities.Transl Neurodegener. 2019 Sep 4;8:28. doi: 10.1186/s40035-019-0172-x. eCollection 2019. Transl Neurodegener. 2019. PMID: 31508228 Free PMC article. Review.
-
Selective targeting of the TLR2/MyD88/NF-κB pathway reduces α-synuclein spreading in vitro and in vivo.Nat Commun. 2021 Sep 10;12(1):5382. doi: 10.1038/s41467-021-25767-1. Nat Commun. 2021. PMID: 34508096 Free PMC article.
-
Dysfunctional energy and future perspective of low dose H2O2 as protective agent in neurodegenerative disease.Heliyon. 2023 Jul 16;9(7):e18123. doi: 10.1016/j.heliyon.2023.e18123. eCollection 2023 Jul. Heliyon. 2023. PMID: 37519743 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
